References
- Salmon S.E., Cassady J.R. Plasma cell neoplasm. Cancer principle and practice of Oncology, 3rd ed., V.T. De Vita, S. Hellman, S.A. Rosenberg. Lippiscott JB, Philadelphia 1989; 1853–1895
- Durie G.B.M., Salmon S.E. A clinical staging system for MM. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842–854
- Alexanian R., Balcerzan S., Bonnett J.D. Prognostic factors in multiple myeloma. Cancer 1975; 1192–1201
- Bataille R., Durie B.G.M., Greinier J., Sany J. Prognostic factors and staging in multiple myeloma: a reaf-frasal. J Clin Oncol 1986; 4(1)80–87
- Brenning G., Simonsson B., Kallander C., Ahre A. Pretreatment serum B2 microglobulin in multiple myeloma. Brit J Haemat 1986; 62: 85–93
- Barlogie B., Smallwood L., Smith T., Alexianian R. High serum levels of lactic dehydrogenase identify a high-grade lymphoma like myeloma. Ann Int Med 1989; 110: 521–525
- Tienhaare A., Pulkki K., Mattile K., Irjala K., Pelliniemi T.T. Serum immunoreactive interleukina 6 and C reactive protein levels in pts with MM at diagnosis. Brit J Heamatol 1994; 86: 391–393
- Bataille R., Boccadoro M., Klein B., Durie B., Pileri A. C reactive protein and B-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733–737
- Greipp P.R., Lust J.A., O'Fallon W.H. Plasmacell labelling index and beta 2 microglobulin predict survival indipendent of thymidine kinase and C reactive protein in MM. Blood 1993; 81: 3382–3387
- Kyle R.A. Prognostic factors in MM. Stem Cells 1995; 13(suppl.2)56–63
- Alexanian R. Diagnosis and management of multiple myeloma. Neoplastic Diseases of the Blood, 2nd ed., P.H. Wiernick, G.P. Canellos, R.A. Kyle, C.A. Sthiffer. Churchill Livingstone, New York 1991; 453–465
- Alexanian R., Barlogie B., Dixon D. Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med 1990; 180: 1693–1695
- Commettee of Chronic Leukemia-Myeloma Task Force. National Cancer Institute. Proposed guidelines protocol studies. Cancer Chemother Rep 1973; 4: 145–158
- Hjorth M., Holmberg E., Rbdjer S., Tanbe A., Westin J. Patient accrual and quality of participation in a multicentre study on myeloma: a comparison between major and minor participating centre. Br J Haemat 1995; 91: 109–115
- Hjorth M., Holmberg E., Rodjer S., Westin J. Impact of active and passive exclusion on the results of a clinical trial in multiple myeloma. Br J Haemat 1992; 80: 55–61
- Taylor K.M., Feldstein M.L., Skeel R.T., Pandya K.J., Peggy N.G., Carbone P.P. Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1737 Eastern Cooperative Oncology Group Investigators. J. Clin Oncol 1994; 12(9)1796–1805
- Decarli A., La Vecchia C. Cancer mortality in Italy. Tumori 1986; 72: 231–240
- Moller Jensen O., Esteve J., Moller M. Cancer in the European Community and its member states. Eur J Cancer 1990; 26(11/12)1167–1254
- Pavlovsky S., Saslavsky J., Texanos Pinto M. A randomized trial of melphalan and prednison versus melphalan, prednisone, cyclophosphamide, MeCCNU and vincristine in untreated MM. J Clin Oncol 1984; 2: 836–40
- Cooper M.R., McIntyre O.R., Propert K.J., Kochwa S., Anderson K., Coleman M., Kyle R.A., Prager D., Rafle S., Zimmer B. Single, sequential and multiple alkylating agent therapy for multiple myeloma: a CALGB study. J Clin Oncol 1986; 4: 1331–1339
- Peest D., Deicher M., Coldewey R., Schmall H.J., Schedel I. Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP. Eur J Cancer Clin Oncol 1988; 24(6)1061–1067
- Boccadoro M., Marmont F., Tribaldo M., Mandelli F. MM: VNCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high risk pts. J Clin Oncol 1991; 9: 444–448
- Gregory W.H., Richards M.A., Malpas J.S. Combination chemotherapy versus melphalan and prednison in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10: 334–342
- Corrado C., Santarelli M.T., Pavlovsky S., Pizzolato M. Prognostic factors in multiple myeloma: definition of risk groups in 410 previously untreated patients: A grupo Argentino de Tratamiento de la Leucemia Aguda Study. J Clin Oncol 1989; 7(12)1839–44
- Hannisdal E., Kildahl-Andersen O., Grottum K.A., Lamvik J. Prognostic factors in multiple myeloma in a population-based trial. Eur J Hematol 1990; 45: 198–202
- Hunter C.P., Frelick R.W., Yate J.W., Feldane A.F., Bavier A.R., Dunlap W.M., Ford L., Henson D., Yancin R. Selection factors in clinical trials: results from the CCOP Physician patient log. Cancer Treat Reports 1987; 71(6)559–565